Migraine in Children: Treatment & Prevention Medications
TL;DR
- Ibuprofen (10 mg/kg) is the first-line acute migraine treatment in children, supported by Level A evidence from the AAN/AHS. Acetaminophen (15 mg/kg) is an alternative.
- Rizatriptan is FDA-approved for ages 6–17; almotriptan for ages 12–17. Other triptans are used off-label with varying evidence.
- No preventive medication clearly outperformed placebo in the landmark CHAMP trial, though topiramate, amitriptyline, and propranolol remain options when attacks are frequent.
- Non-pharmacologic strategies — trigger avoidance, sleep hygiene, and cognitive behavioral therapy — should accompany every treatment plan.
- Red flags (thunderclap onset, focal neurological deficits, worsening pattern) require urgent evaluation to rule out secondary causes.
Understanding Pediatric Migraine
Migraine is not an "adult disease." Population-based studies estimate that 3–10% of school-age children and up to 15–20% of adolescents experience recurrent migraine, making it one of the most common neurological conditions in pediatric practice. Before puberty, boys and girls are affected roughly equally; after menarche, the female-to-male ratio shifts toward approximately 3:1, mirroring the adult pattern.
Pediatric migraine differs from adult migraine in several clinically important ways. Attacks tend to be shorter (sometimes lasting only 1–2 hours, versus the 4–72 hour criterion in adults), more often bilateral rather than strictly unilateral, and more commonly accompanied by prominent gastrointestinal symptoms such as nausea, vomiting, and abdominal pain. The International Classification of Headache Disorders, 3rd edition (ICHD-3) accommodates these differences with modified duration criteria for children.
The burden extends well beyond headache days. Pediatric migraine is associated with significant school absenteeism, reduced quality of life, mood disturbance, and family disruption. Early, evidence-based treatment — both acute and, when indicated, preventive — can substantially reduce this burden.
Acute Treatment: First-Line Options
The 2019 AAN/AHS practice guideline update provides the most current evidence-based framework for acute pediatric migraine treatment. The core principle is early intervention — medications work best when given at the first sign of an attack, before central sensitization develops.
Ibuprofen — The Foundation
Ibuprofen is the only medication with Level A evidence (established efficacy) for acute migraine in children and adolescents. Multiple randomized controlled trials and a Cochrane systematic review confirm its superiority over placebo for pain freedom and pain relief at 2 hours.
Key practical points:
- Dose: 10 mg/kg (maximum 400–600 mg per dose)
- Formulation: Liquid formulations are preferred in younger children for faster absorption, particularly when nausea is present
- Timing: Administer as early as possible in the attack
- Frequency limits: No more than 2–3 days per week to avoid medication-overuse headache
Acetaminophen (Paracetamol)
Acetaminophen at 15 mg/kg (maximum 1000 mg) is a reasonable alternative, particularly in children who cannot tolerate NSAIDs. The evidence base is somewhat weaker — the AAN/AHS guideline classifies it as Level B (probably effective). It has the advantage of fewer gastrointestinal side effects and no antiplatelet activity.
Ibuprofen vs. Acetaminophen: Head-to-Head
| Parameter | Ibuprofen | Acetaminophen |
|---|---|---|
| Evidence level (AAN/AHS) | Level A | Level B |
| Standard dose | 10 mg/kg | 15 mg/kg |
| Maximum single dose | 400–600 mg | 1000 mg |
| Onset of action | ~20–30 min | ~30–45 min |
| 2-hour pain-free rate vs. placebo | Superior (NNT ≈ 4–5) | Probably superior |
| GI side effects | More common | Less common |
| Key contraindications | Renal disease, active GI bleeding, aspirin-sensitive asthma | Hepatic impairment |
| Medication-overuse risk | Yes (>15 days/month) | Yes (>15 days/month) |
Clinical takeaway: Ibuprofen should be tried first unless contraindicated. If one NSAID fails at adequate dose with early administration, switching to the other analgesic class (or escalating to a triptan) is more rational than simply increasing the dose.
Triptans in Pediatric Migraine
Triptans — selective serotonin 5-HT₁B/1D receptor agonists — are the mainstay of acute migraine-specific therapy. However, pediatric trials have historically been complicated by exceptionally high placebo response rates (often 50–60%), making it difficult to demonstrate statistical superiority.
FDA-Approved Triptans for Pediatric Use
Only two triptans carry explicit FDA approval for use in patients under 18:
- Rizatriptan (Maxalt): Approved for patients aged 6–17 years. Available as an orally disintegrating tablet (MLT), which is particularly useful when nausea limits the ability to swallow. Dosing is weight-based: 5 mg for patients <40 kg, 10 mg for those ≥40 kg.
- Almotriptan (Axert): Approved for adolescents aged 12–17 years. Dose: 6.25–12.5 mg orally.
Off-Label Triptans With Supporting Evidence
Several other triptans are used off-label in adolescents, with variable evidence:
- Sumatriptan nasal spray: The AAN/AHS guideline rates this as Level B for adolescents. The nasal route bypasses swallowing and may offer faster onset. A combination product of sumatriptan + naproxen sodium has also shown efficacy in adolescent trials.
- Zolmitriptan nasal spray: Level C evidence in the AAN/AHS guideline. Approved in Europe (EMA) for adolescents aged 12–17.
| Triptan | FDA Pediatric Approval | Age Range | Available Forms | Typical Dose |
|---|---|---|---|---|
| Rizatriptan | Yes | 6–17 years | Tablet, ODT (MLT) | 5 mg (<40 kg), 10 mg (≥40 kg) |
| Almotriptan | Yes | 12–17 years | Tablet | 6.25–12.5 mg |
| Sumatriptan | No (off-label) | Adolescents | Nasal spray, tablet, injection | 5–20 mg nasal; 25–50 mg oral |
| Zolmitriptan | No in US; EMA-approved 12–17 | 12–17 years | Nasal spray, tablet, ODT | 2.5–5 mg nasal |
- Do not use triptans in hemiplegic migraine or migraine with brainstem aura — these are contraindications across all age groups.
- Triptans should not be combined with ergotamines, and caution is warranted with concurrent SSRIs/SNRIs (theoretical serotonin syndrome risk, though clinical significance is debated).
- Medication-overuse headache can develop with triptans used more than 10 days per month.
- Chest tightness ("triptan sensations") can occur and is generally benign, but should be discussed with families in advance to avoid emergency department visits.
Migraine Prevention: When and What to Use
When to Consider Preventive Therapy
The AAN/AHS guidelines suggest considering preventive medication when:
- ≥4 moderate-to-severe migraine days per month (some experts use a lower threshold of ≥3)
- Attacks significantly impair school attendance or daily activities despite optimized acute treatment
- Acute medications are contraindicated, poorly tolerated, or overused
- Migraine variants carry risk of neurological injury (e.g., hemiplegic migraine)
Before starting any preventive medication, clinicians should address modifiable lifestyle factors: irregular sleep, skipped meals, inadequate hydration, excessive caffeine, and psychosocial stressors. These non-pharmacologic interventions are not merely adjunctive — they can be disease-modifying.
The CHAMP Trial — A Paradigm Shift
The Childhood and Adolescent Migraine Prevention (CHAMP) trial, published in the New England Journal of Medicine in 2017, fundamentally changed how clinicians approach pediatric migraine prevention. This rigorously designed, multicenter, double-blind, placebo-controlled trial randomized 328 children and adolescents (aged 8–17 years) to amitriptyline, topiramate, or placebo.
The result: neither amitriptyline nor topiramate was superior to placebo in reducing headache days over 24 weeks. All three groups improved substantially (~50% reduction in headache days), and both active drugs produced significantly more adverse effects than placebo. The trial was stopped early by the Data Safety Monitoring Board on the basis of futility.
The CHAMP trial does not mean these medications never work for individual patients. It does mean that clinicians must be honest with families: the evidence for preventive medications in pediatric migraine is modest at best, and the placebo effect is powerful. Any decision to start preventive therapy should incorporate a careful risk-benefit discussion.
Preventive Medication Options
Despite the CHAMP findings, several medications remain in clinical use when the headache burden is substantial and non-pharmacologic approaches are insufficient.
Amitriptyline
- Class: Tricyclic antidepressant
- Dose: Start 0.25 mg/kg at bedtime (typically 10 mg in adolescents); titrate slowly to 0.5–1 mg/kg/day (maximum ~1 mg/kg/day or 50–75 mg)
- Evidence: Level B (AAN/AHS), though CHAMP was negative
- Advantages: May help comorbid insomnia, tension-type headache, and functional abdominal pain
- Key side effects: Sedation, weight gain, dry mouth, constipation, QTc prolongation
- Monitoring: Baseline ECG recommended (particularly if dose exceeds 0.5 mg/kg or family history of cardiac disease); weight monitoring
Topiramate
- Class: Anticonvulsant
- Dose: Start 0.5–1 mg/kg/day (often 15–25 mg); titrate over 4–8 weeks to 2–3 mg/kg/day (maximum 100–200 mg/day in divided doses)
- Evidence: Level B (AAN/AHS); FDA-approved for migraine prevention in adults, but not in children
- Advantages: Weight-neutral or weight-reducing (helpful in obese adolescents); may help comorbid epilepsy
- Key side effects: Cognitive slowing ("brain fog"), word-finding difficulty, paresthesias, metabolic acidosis, nephrolithiasis, weight loss (potentially problematic in underweight children)
- Monitoring: Serum bicarbonate at baseline and periodically; weight; academic performance
Propranolol
- Class: Non-selective beta-blocker
- Dose: Start 0.5–1 mg/kg/day in 2–3 divided doses; titrate to 2–4 mg/kg/day (maximum typically 120 mg/day in adolescents)
- Evidence: Level B (AAN/AHS)
- Advantages: Well-studied safety profile in pediatrics (long history of use for other indications); may help comorbid anxiety and performance anxiety
- Key side effects: Fatigue, exercise intolerance, bradycardia, hypotension, bronchospasm
- Contraindications: Asthma (absolute), diabetes (may mask hypoglycemia), sinus bradycardia, heart block
Other agents used less commonly:
- Cyproheptadine: An antihistamine with antiserotonergic properties, sometimes used in younger children (aged 2–6 years) at 0.25–0.5 mg/kg/day. Evidence is limited (Level C), but the favorable safety profile makes it a pragmatic choice in this age group.
- Valproate/divalproex sodium: Has some evidence in adults but is generally avoided in pediatric migraine due to teratogenicity risk (critical in adolescent females), hepatotoxicity, weight gain, and hair loss. The AAN/AHS guideline does not recommend it as first-line.
- CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab): These newer agents, approved for adult migraine prevention, are being studied in adolescent populations. Preliminary data are emerging, but as of 2025, none carry FDA approval for patients under 18. Off-label use in refractory adolescent cases is reported but should be considered only after failure of conventional options and ideally within a specialist setting.
Practical Approach to Prevention
| Factor | Amitriptyline | Topiramate | Propranolol |
|---|---|---|---|
| Starting dose | 0.25 mg/kg/day | 0.5–1 mg/kg/day | 0.5–1 mg/kg/day |
| Target dose | 0.5–1 mg/kg/day | 2–3 mg/kg/day | 2–4 mg/kg/day |
| Helpful comorbidities | Insomnia, anxiety, depression | Epilepsy, obesity | Anxiety, tremor |
| Weight effect | Gain | Loss | Neutral |
| Cognitive effects | Minimal | Word-finding difficulty, slowed processing | Minimal |
| Key monitoring | ECG, weight | Bicarbonate, weight, cognition | HR, BP, exercise tolerance |
| Avoid if | Cardiac conduction disease, obesity | Kidney stones, underweight, cognitive concerns | Asthma, diabetes |
Duration of preventive therapy: A typical trial should last at least 8–12 weeks at therapeutic dose before judging efficacy. If effective, most experts recommend continuing for 6–12 months before attempting a supervised taper. Abrupt discontinuation should be avoided, particularly with beta-blockers and tricyclics.
Non-Pharmacologic Strategies
Medications alone are rarely sufficient, and guidelines uniformly emphasize a multimodal approach.
Cognitive behavioral therapy (CBT): The strongest non-pharmacologic evidence supports CBT, both alone and combined with pharmacotherapy. The CHAMP trial's robust placebo response likely reflects, in part, the structured attention and headache education all participants received. CBT teaches children to identify triggers, manage stress, and apply relaxation techniques.
Biofeedback: Thermal biofeedback and electromyographic (EMG) biofeedback have Level B evidence for pediatric migraine prevention. These techniques appeal to many families seeking non-drug approaches.
Lifestyle modification (the "SEEDS" framework):
- Sleep: Regular sleep schedule (8–10 hours for school-age children)
- Exercise: Regular aerobic activity (≥30 minutes, 3–5 times per week)
- Eat: Consistent meal timing; adequate hydration
- Diary: Headache diary to identify triggers and track treatment response
- Stress management: Mindfulness, relaxation, school accommodations if needed
Nutraceuticals: Some clinicians trial riboflavin (vitamin B₂, 200–400 mg/day), magnesium (9 mg/kg/day in divided doses), or coenzyme Q10 (1–3 mg/kg/day). Evidence is limited and largely extrapolated from adult studies, but the favorable safety profiles make these reasonable adjuncts, particularly when families prefer to avoid prescription medications.
Side Effects and Monitoring
All preventive medications require ongoing monitoring, both for efficacy and safety.
Medication-overuse headache (MOH) is a critical — and often underrecognized — concern in pediatric migraine. Any acute medication used excessively can transform episodic migraine into a chronic daily pattern:
- Simple analgesics (ibuprofen, acetaminophen): Risk increases with use ≥15 days/month
- Triptans, combination analgesics, opioids: Risk increases with use ≥10 days/month
Education about MOH should be part of every initial migraine consultation. Treatment involves gradual withdrawal of the overused medication, often with bridge therapy and initiation of a preventive agent.
Contraindications and Drug Interactions
| Medication | Absolute Contraindications | Important Interactions |
|---|---|---|
| Ibuprofen | Active GI bleeding, severe renal impairment, aspirin-sensitive asthma | Anticoagulants (increased bleeding risk), lithium, methotrexate, ACE inhibitors |
| Rizatriptan | Hemiplegic migraine, ischemic heart disease, uncontrolled hypertension, use within 24 hours of ergotamines | Propranolol (increases rizatriptan levels — use 5 mg dose), MAOIs |
| Almotriptan | Same as other triptans | CYP3A4 inhibitors (ketoconazole, erythromycin) |
| Amitriptyline | Recent MI, concurrent MAOI use, known QTc prolongation | SSRIs (serotonin syndrome), CYP2D6 inhibitors (fluoxetine — increases amitriptyline levels) |
| Topiramate | Metabolic acidosis, nephrolithiasis (relative) | Valproate (increased ammonia, hypothermia risk), hormonal contraceptives (reduced efficacy) |
| Propranolol | Asthma, sinus bradycardia, heart block >1st degree, cardiogenic shock | Calcium channel blockers (additive cardiac effects), insulin/sulfonylureas (masked hypoglycemia) |
Special Populations
Very Young Children (Under 6 Years)
Migraine in preschool-age children can be particularly challenging to diagnose and treat. These children often cannot articulate their symptoms and may present primarily with behavioral changes, pallor, and vomiting. Ibuprofen and acetaminophen remain first-line acute treatments. Cyproheptadine is the most commonly used preventive in this age group, though evidence is limited.
Adolescent Females
Menstrual migraine is common in adolescent girls. Short-term perimenstrual prophylaxis with naproxen sodium (starting 1–2 days before expected menses) or a triptan can be effective. When considering topiramate, clinicians must counsel about its teratogenic potential and its interaction with hormonal contraceptives — topiramate reduces the efficacy of combined oral contraceptives at doses ≥200 mg/day.
Children With Comorbid Epilepsy
Topiramate and valproate are anticonvulsants with migraine preventive properties, making them logical choices in children with both conditions. However, the side-effect profiles must be weighed carefully. Avoid combining valproate with topiramate due to the risk of hyperammonemia and hypothermia.
Children With Comorbid Anxiety or Depression
Psychiatric comorbidities are common in pediatric migraine. Amitriptyline may offer dual benefit for migraine and comorbid anxiety/insomnia. Propranolol can help performance-related anxiety. If an SSRI/SNRI is needed for depression, monitor carefully when combined with triptans (theoretical serotonin syndrome risk).
Red Flags — When to Seek Urgent Medical Attention
Parents and caregivers should be counseled to seek immediate medical evaluation if any of the following occur:
- Thunderclap headache — sudden onset reaching maximum intensity within seconds to minutes
- New neurological deficits — weakness, vision loss, speech difficulty, or confusion that persist beyond the typical aura duration (>60 minutes)
- Progressive worsening pattern — headaches increasing in frequency or severity over weeks despite treatment
- Headache awakening the child from sleep consistently
- Headache with fever, neck stiffness, and photophobia — meningitis must be excluded
- New headache after head trauma
- Change in personality or school performance — may suggest raised intracranial pressure
- Headache in a child under 3 years — secondary causes are more common in this age group
- Papilledema on examination
These features do not necessarily indicate a dangerous condition, but they warrant neuroimaging (typically MRI) and/or specialist referral to exclude secondary headache disorders.
Frequently Asked Questions
Q: Is my child too young for migraine medication? A: No age is "too young" for appropriate acute treatment. Ibuprofen and acetaminophen are safe and effective at weight-based doses in children as young as 6 months. Triptans are approved from age 6 (rizatriptan) or 12 (almotriptan). Preventive decisions depend on headache burden, not age alone, though the choice of agent may differ — cyproheptadine is often preferred in children under 6.
Q: Can my child take ibuprofen and a triptan together? A: Yes. Combining an NSAID with a triptan is a well-established strategy in adults, and the combination of sumatriptan + naproxen has been studied in adolescents. Clinicians often recommend taking ibuprofen first and adding a triptan if pain persists after 1–2 hours, or using both simultaneously for severe attacks. This should be done under medical guidance.
Q: The CHAMP trial found preventive medications didn't work — should my child even try them? A: The CHAMP trial found that, on average, amitriptyline and topiramate were not better than placebo across the study population. However, individual patients may still respond. The trial also showed that all groups — including placebo — improved significantly, underscoring the importance of structured headache management, education, and lifestyle optimization. Preventive medication remains a reasonable option for children with high headache burden, but expectations should be realistic.
Q: Are CGRP antibodies (like Aimovig) available for children? A: As of early 2026, no CGRP-targeting medication (monoclonal antibodies or gepants) has FDA approval for patients under 18. Clinical trials in adolescents are ongoing. Off-label use is occasionally considered in specialized headache centers for refractory cases, but this is not routine practice.
Q: How long should my child stay on preventive medication? A: Most guidelines recommend a minimum trial of 8–12 weeks at therapeutic dose. If effective, treatment typically continues for 6–12 months, followed by a slow taper. Many children "outgrow" their migraine pattern, particularly boys, making periodic reassessment important.
Q: Should my child avoid specific foods to prevent migraines? A: Blanket dietary restrictions are not recommended by guidelines. While some children identify specific food triggers (chocolate, aged cheese, processed meats, artificial sweeteners), trigger identification should be individualized using a headache diary. Eliminating entire food groups without documented trigger association can lead to nutritional deficiency and unnecessary restriction in growing children. Consistent meal timing and adequate hydration are more evidence-based strategies than specific food avoidance.
Q: Can my child still play sports? A: In most cases, yes. Regular aerobic exercise is actually associated with reduced migraine frequency. However, children on propranolol may experience exercise intolerance due to blunted heart rate response. For children whose migraines are triggered by exertion or dehydration, ensuring adequate hydration before activity and considering pre-exercise analgesic prophylaxis (under medical guidance) can help. There is no general recommendation to restrict sports in children with migraine.
Q: What about devices like Cefaly or gammaCore for children? A: Neuromodulation devices are FDA-cleared for migraine in adults, and some (e.g., transcutaneous supraorbital nerve stimulation) have been studied in small pediatric trials with promising early results. They are generally well-tolerated but not yet broadly recommended in pediatric guidelines due to limited evidence. They may be considered for adolescents who prefer non-pharmacologic approaches or have contraindications to medications.
References
-
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology. 2019;93(16):700-715. PMID: 31413171
-
Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology. 2019;93(16):691-699. PMID: 31413170
-
Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115-124. PMID: 28079092
-
Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4(4):CD005220. PMID: 27091010
-
NICE. Headaches in over 12s: diagnosis and management. Clinical guideline CG150. 2021 (updated). nice.org.uk/guidance/cg150
-
FDA. Prescribing information: Maxalt (rizatriptan benzoate). 2022. accessdata.fda.gov
-
Hershey AD, Powers SW, Vockell AL, et al. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology. 2001;57(11):2034-2039. PMID: 11739822
-
Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache. 2007;47(4):511-518. PMID: 17445100
-
Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088-1097. PMID: 20875042
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in evidence-based medication therapy. He has worked across hospital, ambulatory, and consulting pharmacy settings, with particular expertise in translating complex clinical evidence into practical guidance for healthcare professionals and informed patients. Dr. Ozarchuk writes for PillsCard.com, an international drug encyclopedia committed to delivering accurate, up-to-date pharmaceutical information grounded in peer-reviewed evidence and current clinical guidelines.
Medical Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects current evidence and guidelines at the time of writing but may not encompass all clinical scenarios. Always consult a qualified healthcare professional — such as a pediatrician, pediatric neurologist, or clinical pharmacist — before starting, stopping, or changing any medication for a child. Individual treatment decisions must account for the patient's specific medical history, comorbidities, concurrent medications, and clinical context. PillsCard.com and the author assume no liability for actions taken based on the content of this article.